U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H24FN3OS
Molecular Weight 397.509
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIMIPERONE

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)N3C(=S)NC4=C3C=CC=C4

InChI

InChIKey=YDLQKLWVKKFPII-UHFFFAOYSA-N
InChI=1S/C22H24FN3OS/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)

HIDE SMILES / InChI

Molecular Formula C22H24FN3OS
Molecular Weight 397.509
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://medical.mt-pharma.co.jp/di/file/dc/tol_f.htm https://www.medicallibrary-dsc.info/di/tolopelon_tablets_3mg/pdf/if_tp_tab_1301_09.pdf

Timiperone is a neuroleptic agent that was developed in Japan. Timiperone has a potent antipsychotic activity, which is comparable to other butyrophenones such as haloperidol (HAL). Timiperone has a five-eight-times higher affinity to dopamine receptors and a 15-times higher affinity to serotonin receptors than those of HAL. Clinical trials have suggested that TIM has a specific action against negative symptoms such as lack of initiative or blunted affect as well as positive symptoms such as delusions and hallucinations in schizophrenics.

Originator

Curator's Comment: Timiperone was created in 1973 by Daiichi Pharmaceutical Co., Ltd. (currently: Daiichi Sankyo Co., Ltd.).

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Tolopelon

Approved Use

Timiperone is efficient against schizophrenia.

Launch Date

1983
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.947 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIMIPERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
13.6 ng/mL
4 mg single, intramuscular
dose: 4 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TIMIPERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
39.321 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIMIPERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
175.3 ng × h/mL
4 mg single, intramuscular
dose: 4 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TIMIPERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.906 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIMIPERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
15.7 h
4 mg single, intramuscular
dose: 4 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
TIMIPERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound
Doses

Doses

DosePopulationAdverse events​
18 mg 1 times / day steady-state, oral
Studied dose
Dose: 18 mg, 1 times / day
Route: oral
Route: steady-state
Dose: 18 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.
2004-11-26
Effect of hyperprolactinemia induced by pituitary grafts or castration on porphyrin content of the mouse Harderian gland.
2001-08
Patents

Sample Use Guides

Dosage gradually increase from 0,5-3 mg to 3-12 mg daily during 12 weeks
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:19:13 GMT 2025
Edited
by admin
on Mon Mar 31 18:19:13 GMT 2025
Record UNII
626DQ7N19L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIMIPERONE
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
TOLOPELON
Preferred Name English
timiperone [INN]
Common Name English
TIMIPERONE [MI]
Common Name English
TIMIPERONE [MART.]
Common Name English
TIMIPERONE [JAN]
Common Name English
DD-3480
Code English
4-FLUORO-4-(4-(2-THIOXO-1-BENZIMIDAZOLINYL)PIPERIDINO)BUTYROPHENONE
Systematic Name English
Timiperone [WHO-DD]
Common Name English
1-BUTANONE, 4-(4-(2,3-DIHYDRO-2-THIOXO-1H-BENZIMIDAZOL-1-YL)-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C28197
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
Code System Code Type Description
DRUG CENTRAL
2668
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
PUBCHEM
3033151
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
SMS_ID
100000077222
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
WIKIPEDIA
TIMIPERONE
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
260-880-9
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
INN
4525
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
NCI_THESAURUS
C76451
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL2107117
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
CAS
57648-21-2
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
FDA UNII
626DQ7N19L
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
MERCK INDEX
m10870
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY Merck Index
EVMPD
SUB11065MIG
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
MESH
C024159
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID9023673
Created by admin on Mon Mar 31 18:19:13 GMT 2025 , Edited by admin on Mon Mar 31 18:19:13 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY